Prosecution Insights
Last updated: May 29, 2026
Application No. 18/070,870

COATINGS CONTAINING ENZYME FOR STABLE SELF-CLEANING OF ORGANIC STAINS

Final Rejection §DOUBLEPATENT
Filed
Nov 29, 2022
Priority
Sep 09, 2011 — continuation of 9121016 +2 more
Examiner
CONSTANTINE, CHARLES Z
Art Unit
1657
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Regents Of The University Of Minnesota
OA Round
3 (Final)
58%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
246 granted / 421 resolved
-1.6% vs TC avg
Strong +49% interview lift
Without
With
+49.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
12 currently pending
Career history
444
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
50.3%
+10.3% vs TC avg
§102
9.2%
-30.8% vs TC avg
§112
12.9%
-27.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 421 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 03/17/2026 has been entered. Response to Arguments In light of the terminal disclaimer filed to USP 10,988,714, the double patenting rejection to this patent is therefore obviated. Applicant argues that application 18763584 has not yet been patented and that the rejection is not yet ripe. This description of a provisional double patenting rejection does not negate the rejection, this rejection is therefore maintained. As this rejection has been previously made, this action is made final. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based electronic Terminal Disclaimer may be filled out completely online using web-screens. An electronically filed Terminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claim 1-9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of copending Application No. 18763584 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because ‘584 claims a coatings which have aggregates of less than 5 micrometers, claim that the coating may be formed from a two component solvent borne composition. ‘584 further claims the enzyme may be by PEGylation including by a branched PEG, and having molecular weight greater than 10,000 Da and that the enzyme may be a hydrolase such as a lipase. ‘584 further claims that the composition may comprise a secondary polyethylene and further claims ranges which overlap with the ranges claimed. Further one of ordinary skill would instantly envisage that branched or linear polyoxyethylene could be used as these are the two common structure so classes of the polymer. Further urethane linkage for pegylation is taught by ‘584 and thus within the scope of the claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion No claim is allowed. All claims are identical to or patentably indistinct from, or have unity of invention with claims in the application prior to the entry of the submission under 37 CFR 1.114 (that is, restriction (including a lack of unity of invention) would not be proper) and all claims could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARLES Z CONSTANTINE whose telephone number is (571)270-5533. The examiner can normally be reached Mon-Fri 9-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Louise Humphrey can be reached at 571-272-5543. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARLES Z CONSTANTINE/Examiner, Art Unit 1657 /ROBERT J YAMASAKI/Primary Examiner, Art Unit 1657
Read full office action

Prosecution Timeline

Nov 29, 2022
Application Filed
Feb 11, 2025
Non-Final Rejection mailed — §DOUBLEPATENT
Jun 10, 2025
Response Filed
Oct 17, 2025
Final Rejection mailed — §DOUBLEPATENT
Mar 17, 2026
Request for Continued Examination
Mar 20, 2026
Response after Non-Final Action
Apr 01, 2026
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12612653
NOVEL POLYPEPTIDES FOR PRODUCING ALBICANOL AND/OR DRIMENOL COMPOUNDS
4y 1m to grant Granted Apr 28, 2026
Patent 12492418
METHOD FOR PREPARING THEAFLAVIN WITH IMMOBILIZED SUBSTRATE
10m to grant Granted Dec 09, 2025
Patent 12473582
METHOD AND AGENTS FOR DETECTING LUCIFERASE ACTIVITY
2y 1m to grant Granted Nov 18, 2025
Patent 12435348
MICROBIAL CELLS FOR SPERMIDINE PRODUCTION
5y 9m to grant Granted Oct 07, 2025
Patent 12421481
PHOTON-INDUCED ACCELERATED ENZYMES AND BIOACTIVE COMPOUNDS ACCUMULATION IN BARLEY DURING MALTING
3y 2m to grant Granted Sep 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+49.3%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 421 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month